08:00 , Dec 4, 2014 |  BC Innovations  |  Distillery Therapeutics

Indication: Cardiovascular disease

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cardiovascular disease Myocardial infarction (MI) SWI/SNF related matrix associated actin dependent regulator of chromatin subfamily a member 5 (SMARCA5;...
08:00 , Jan 9, 2014 |  BC Innovations  |  Tools & Techniques

Silencing KRAS

Oncogenic KRAS is notoriously difficult to target because of a lack of well-defined surface pockets for drug binding. Nucleic acid therapeutics can bypass that issue but have their own problems including tissue targeting, cellular uptake...
08:00 , Dec 19, 2013 |  BC Innovations  |  Distillery Techniques

Technology: Drug platforms

Approach Summary Licensing status Publication and contact information Drug platforms Lin-28 homolog A (LIN28A)-dependent metabolic reprogramming for tissue repair Mouse studies suggest elevating LIN28A activity could help promote...
08:00 , Jan 2, 2012 |  BC Week In Review  |  Company News

Marina Biotech, Mirna deal

The companies partnered to develop microRNA-based targeted cancer therapies using Marina's SMARTICLES liposomal-based delivery technology and Mirna's miRNAs. Marina is eligible to receive up to $63 million total in upfront and milestone payments, as well...
07:00 , Apr 26, 2010 |  BC Week In Review  |  Clinical News

Regulus preclinical data

In a diet-induced obesity mouse model of diabetes, twice-weekly subcutaneous oligonucleotides targeting microRNA let-7 ( MIRLET7; LET-7) for 6 weeks improved insulin resistance by 75% as measured by insulin response during an oral...
07:00 , Jun 11, 2009 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer ...
07:00 , Jun 1, 2009 |  BioCentury  |  Emerging Company Profile

Asuragen: Cutting pancreatic surgeries

Patients with pancreatic cancer and pancreatitis present with similar symptoms, and are often given ultrasound tests to confirm the presence or absence of lesions. About 15% of these tests are inconclusive, and as a result...
08:00 , Nov 20, 2008 |  BC Innovations  |  Tools & Techniques

Micromanaging oncolytic viruses

Oncolytic viruses have had limited success as cancer therapies, largely because of the need to balance potent antitumor activity with off-target toxicity. Two research teams have now applied a microRNA-based strategy that could restrict the...
07:00 , Aug 21, 2008 |  BC Innovations  |  Cover Story

Stressing Out Over miRNA

Two papers, one published in the Proceedings of the National Academy of Sciences 1 and the other in Nature Immunology,2 identify several microRNAs that play a role in cellular stress triggered by myocardial infarction or...
07:00 , Apr 7, 2008 |  BC Week In Review  |  Company News

Asuragen cancer news

Asuragen spun out Mirna Therapeutics Inc. to develop and commercialize microRNA (miRNA) cancer therapeutics. Asuragen is transferring its IP covering miRNA therapeutics to Mirna, including exclusive rights to let-7, an miRNA in preclinical testing...